Our Program
EO-1022, a HER3 ADC
Elevation Oncology is developing EO-1022, a potentially differentiated HER3 ADC for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody, site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4.
EO-1022 leverages seribantumab’s desirable internalization properties and advanced site-specific ADC technology which makes possible the use of the potent cytotoxic MMAE payload.
Elevation Oncology expects to file an Investigational New Drug (IND) application in 2026.
Compassionate Use Statement
Expanded access, also referred to as compassionate use, is a pathway that allows the use of an investigational drug for treatment use prior to regulatory approval and outside of a clinical trial when no comparable alternative therapy options are available.
Elevation Oncology is committed to developing selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. To make novel therapies more widely available to patients, Elevation Oncology conducts clinical trials to evaluate the safety and efficacy of investigational therapies to support regulatory approval. Patients are encouraged to speak with their treating physician about their potential treatment options and participation in clinical trials, if appropriate.
Currently, Elevation Oncology does not have an expanded access or compassionate use program for any of our investigational products outside of enrollment in our clinical trials anywhere in the world. We encourage you to stay informed regarding our development programs.